Lanreotid Amdipharm (Lanreotide)
Somatostatin analogue for acromegaly and neuroendocrine tumours
Quick Facts About Lanreotid Amdipharm
Key Takeaways
- Lanreotid Amdipharm is a prescription-only somatostatin analogue given as a deep subcutaneous injection every 28 days for treatment of acromegaly and neuroendocrine tumours.
- It works by binding to somatostatin receptors (SSTR2 and SSTR5), reducing excess growth hormone, IGF-1, and other hormonal secretions.
- Gallstones are a very common side effect — regular ultrasound monitoring of the gallbladder is recommended during treatment.
- Blood glucose levels may be affected; patients with diabetes require closer monitoring while on lanreotide therapy.
- The medication must be stored in a refrigerator (2–8°C) and is not recommended during pregnancy or breastfeeding unless clearly necessary.
What Is Lanreotid Amdipharm and What Is It Used For?
Quick Answer: Lanreotid Amdipharm contains lanreotide, a synthetic analogue of the naturally occurring hormone somatostatin. It is primarily used to treat acromegaly and gastroenteropancreatic neuroendocrine tumours (GEP-NETs), working by suppressing excess hormone production.
Lanreotide belongs to a class of medications known as somatostatin analogues. The naturally occurring hormone somatostatin is produced in the hypothalamus, gastrointestinal tract, and pancreas. It plays a crucial role in regulating the endocrine system by inhibiting the secretion of multiple hormones, including growth hormone (GH), thyroid-stimulating hormone (TSH), insulin, and glucagon. However, natural somatostatin has a very short half-life of approximately 1–3 minutes, making it impractical for therapeutic use. Lanreotide was developed as a synthetic octapeptide analogue with a much longer duration of action, allowing for once-monthly dosing.
The primary clinical indications for Lanreotid Amdipharm include the treatment of acromegaly, a rare hormonal disorder caused by a pituitary adenoma that secretes excess growth hormone. In acromegaly, elevated GH and IGF-1 levels lead to progressive enlargement of the hands, feet, and facial features, along with systemic complications including cardiovascular disease, diabetes mellitus, arthropathy, and sleep apnoea. Lanreotide effectively reduces GH and IGF-1 levels in many patients, helping to control symptoms and prevent long-term complications. According to data from the European Medicines Agency (EMA), lanreotide normalises GH levels in approximately 50–70% of patients and IGF-1 levels in 40–60% of patients.
The second major indication is for gastroenteropancreatic neuroendocrine tumours (GEP-NETs). These are relatively rare tumours arising from neuroendocrine cells in the gastrointestinal tract or pancreas. They may be functional (secreting hormones that cause symptoms such as flushing, diarrhoea, and wheezing — collectively known as carcinoid syndrome) or non-functional. The landmark CLARINET trial, published in the New England Journal of Medicine in 2014, demonstrated that lanreotide autogel significantly prolonged progression-free survival in patients with metastatic GEP-NETs compared to placebo, establishing its role in antiproliferative therapy for these tumours.
Additionally, lanreotide is used to manage the symptomatic manifestations of carcinoid syndrome, including severe diarrhoea, flushing episodes, and wheezing, by reducing the secretion of serotonin and other vasoactive substances from the tumour. Treatment with lanreotide can significantly improve quality of life for patients suffering from these debilitating symptoms.
Mechanism of Action
Lanreotide exerts its therapeutic effects by binding primarily to somatostatin receptor subtypes 2 (SSTR2) and 5 (SSTR5), with lower affinity for SSTR1, SSTR3, and SSTR4. The SSTR2 subtype is particularly important as it is the predominant receptor on growth hormone-secreting pituitary adenomas and on many neuroendocrine tumour cells. By activating these receptors, lanreotide triggers a cascade of intracellular signalling events that result in the inhibition of hormone secretion, reduction of cell proliferation, and potential induction of apoptosis in tumour cells.
After deep subcutaneous injection, the lanreotide in the pre-filled syringe forms a gel depot at the injection site. This depot slowly releases the active substance over the course of approximately 28 days, maintaining therapeutic drug levels throughout the dosing interval. The bioavailability of subcutaneous lanreotide is approximately 60–70%, with a terminal half-life of 23–30 days, supporting the once-monthly dosing regimen.
What Should You Know Before Taking Lanreotid Amdipharm?
Quick Answer: Before starting Lanreotid Amdipharm, your doctor needs to assess your gallbladder health, thyroid function, glucose metabolism, and cardiac status. This medication is contraindicated in patients with known hypersensitivity to lanreotide or any of its excipients.
Before initiating treatment with Lanreotid Amdipharm, a thorough medical evaluation is essential. Your prescribing physician will review your complete medical history, current medications, and any pre-existing conditions that may influence the safety and efficacy of the treatment. The decision to start lanreotide therapy should involve a multidisciplinary team, particularly when the drug is being used for neuroendocrine tumour management.
Contraindications
Lanreotid Amdipharm is contraindicated in patients with known hypersensitivity to lanreotide, to any other somatostatin analogue, or to any of the excipients contained in the formulation. Hypersensitivity reactions, including anaphylaxis, have been reported rarely with somatostatin analogues. Patients who have experienced a serious allergic reaction to octreotide (another somatostatin analogue) should be assessed carefully before starting lanreotide, as cross-reactivity is possible.
Warnings and Precautions
Gallbladder disorders: Somatostatin analogues are well-known to affect gallbladder motility and bile composition, significantly increasing the risk of gallstone formation (cholelithiasis). Studies indicate that gallstones develop in approximately 15–30% of patients receiving long-term somatostatin analogue therapy. Periodic ultrasound examination of the gallbladder is recommended both before starting treatment and at regular intervals (typically every 6–12 months) during therapy. Patients should be informed about the signs and symptoms of gallbladder disease, including right upper quadrant pain, nausea, and jaundice.
Glucose metabolism: Lanreotide can affect glucose homeostasis through its inhibitory effects on insulin and glucagon secretion. In some patients, this may lead to hyperglycaemia (elevated blood sugar), while in others, particularly those with insulinomas, hypoglycaemia (low blood sugar) may occur. Patients with diabetes mellitus or impaired glucose tolerance require closer glycaemic monitoring during treatment, and adjustments to antidiabetic medications may be necessary. The European Society of Endocrinology recommends HbA1c monitoring every 3–6 months in patients with pre-existing diabetes who are on somatostatin analogue therapy.
Thyroid function: Lanreotide may slightly decrease thyroid-stimulating hormone (TSH) secretion. Although clinically significant hypothyroidism is uncommon, monitoring of thyroid function is advisable, particularly in patients with pre-existing thyroid disorders. Periodic assessment of free T4 and TSH levels is recommended.
Cardiac effects: Somatostatin analogues have been associated with bradycardia (slow heart rate). Patients with underlying cardiac conduction abnormalities, those taking medications that affect heart rate (such as beta-blockers or calcium channel blockers), or those with a history of arrhythmias should have their cardiac function monitored carefully. Baseline and periodic electrocardiogram (ECG) monitoring may be appropriate in at-risk patients.
If you experience sudden severe abdominal pain, persistent nausea, vomiting, fever, or yellowing of the skin or eyes during treatment with lanreotide, seek medical attention immediately. These symptoms may indicate gallbladder complications such as cholecystitis or biliary obstruction, which require urgent medical evaluation.
Pregnancy and Breastfeeding
Pregnancy: There is limited data on the use of lanreotide in pregnant women. Animal reproductive studies have shown some evidence of adverse effects, including reduced foetal weight and delayed ossification, although no teratogenic effects were observed at therapeutic doses. As a precautionary measure, Lanreotid Amdipharm is not recommended during pregnancy unless the potential benefit justifies the potential risk to the foetus. Women of childbearing potential should use effective contraception during treatment and for at least 6 months following the last injection.
Breastfeeding: It is not known whether lanreotide is excreted in human breast milk. Given the potential for adverse reactions in the nursing infant, a decision must be made whether to discontinue breastfeeding or to discontinue lanreotide therapy, taking into account the importance of the drug to the mother. Most international guidelines recommend against breastfeeding during lanreotide treatment.
How Does Lanreotid Amdipharm Interact with Other Drugs?
Quick Answer: Lanreotide can interact with several medications, most notably drugs affecting heart rate, blood glucose levels, and ciclosporin. Your doctor should review all current medications before starting treatment.
Drug interactions with lanreotide primarily arise from its pharmacological effects on hormone secretion, gastrointestinal motility, and cardiac function. While lanreotide is not extensively metabolised by the cytochrome P450 enzyme system (reducing the risk of metabolic drug interactions), its physiological effects can alter the absorption, distribution, or efficacy of co-administered medications. Healthcare professionals should conduct a thorough medication review before initiating lanreotide therapy and at each follow-up visit.
Major Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Ciclosporin (Cyclosporine) | Lanreotide may reduce intestinal absorption of ciclosporin, leading to decreased blood levels | Monitor ciclosporin trough levels closely; dose adjustment may be required |
| Insulin & Oral Antidiabetics | Lanreotide alters glucose homeostasis by suppressing insulin and glucagon secretion | Frequent blood glucose monitoring; antidiabetic dose adjustment may be needed |
| Beta-blockers | Additive bradycardic effect when combined with lanreotide | Monitor heart rate and ECG; dose reduction of beta-blocker may be necessary |
| Quinidine | Combined risk of cardiac conduction abnormalities and QT prolongation | ECG monitoring recommended; use combination with caution |
Minor Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Bromocriptine | Increased bioavailability of bromocriptine when co-administered with lanreotide | Monitor for bromocriptine side effects; dose reduction may be considered |
| Calcium channel blockers | Potential additive effect on heart rate reduction | Monitor heart rate; generally well tolerated in combination |
| Oral contraceptives | Theoretical reduction in absorption due to altered GI motility | Use additional contraceptive measures if breakthrough bleeding occurs |
The above interactions are not exhaustive. Always inform your healthcare provider about all prescription drugs, over-the-counter medications, herbal supplements, and vitamins you are taking. This is particularly important for medications with narrow therapeutic indices, where small changes in blood levels can have significant clinical consequences.
What Is the Correct Dosage of Lanreotid Amdipharm?
Quick Answer: The standard dose of Lanreotid Amdipharm is 60 mg administered as a deep subcutaneous injection every 28 days. The dose and frequency may be adjusted based on clinical response, GH/IGF-1 levels, and the specific condition being treated.
Lanreotid Amdipharm is available as a 60 mg solution for injection in a pre-filled syringe. The medication is intended for deep subcutaneous injection only — it must not be administered intravenously. The preferred injection site is the upper outer quadrant of the buttock, alternating between left and right sides with each injection. The injection should be performed by a healthcare professional, although self-injection or injection by a trained carer may be considered after appropriate training has been provided by the prescribing clinic.
Adults
Acromegaly
The recommended starting dose is 60 mg every 28 days. Dose adjustments should be based on serum GH and IGF-1 levels, measured at 3-month intervals. If GH levels remain above 2.5 ng/mL and/or IGF-1 remains above the age- and sex-adjusted normal range after at least 3 months of treatment, the dose may be increased. Lanreotide is also available in higher strengths (90 mg and 120 mg) from other manufacturers for patients requiring dose escalation. Conversely, if GH and IGF-1 levels are well controlled, the dosing interval may be extended in some patients.
Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs)
For the treatment of unresectable, well-differentiated or moderately differentiated, locally advanced or metastatic GEP-NETs, the recommended dose is 60 mg every 28 days. Treatment should continue as long as there is evidence of clinical benefit, typically until disease progression. Based on the CLARINET study, some patients may benefit from escalation to higher-dose formulations. Tumour response should be assessed with imaging studies (CT or MRI) and biochemical markers (chromogranin A, 5-HIAA) at regular intervals, typically every 3–6 months.
Carcinoid Syndrome
For symptomatic control of carcinoid syndrome, the initial dose is 60 mg every 28 days. Dose and frequency adjustments are guided by symptom control. Patients with persistent symptoms may require dose escalation or supplementary short-acting octreotide for breakthrough symptom management.
Children and Adolescents
The safety and efficacy of Lanreotid Amdipharm in children and adolescents under 18 years have not been established. There is insufficient clinical data to recommend a dose in this age group. Paediatric use should only be considered in exceptional circumstances under specialist supervision, and no specific dosage recommendations can be made based on currently available evidence.
Elderly Patients
No specific dose adjustment is required for elderly patients (65 years and older). Clinical studies have included patients up to 80 years of age, and no age-related differences in safety or efficacy have been observed. However, given the higher prevalence of hepatic, renal, and cardiac comorbidities in elderly patients, careful clinical monitoring is advisable, particularly during the initial phase of treatment.
Renal and Hepatic Impairment
Formal pharmacokinetic studies in patients with severe renal or hepatic impairment are limited. In patients with moderate renal impairment, no dose adjustment is required. However, caution is advised in severe renal impairment (creatinine clearance <30 mL/min), and the starting dose may need to be reduced. Similarly, patients with moderate to severe hepatic impairment may exhibit increased lanreotide exposure, and dose adjustments guided by clinical response and tolerability are recommended.
Missed Dose
If you miss a scheduled injection, contact your healthcare provider as soon as possible to arrange an appointment. The missed dose should be administered as soon as practical, and subsequent doses should be scheduled at 28-day intervals from the new injection date. Do not double the dose to compensate for a missed injection. If the delay between injections exceeds 35 days, symptoms may recur, and your doctor may recommend interim supportive measures.
Overdose
In the event of an overdose with Lanreotid Amdipharm, there is no specific antidote. Management should be symptomatic and supportive. Symptoms of overdose may include severe nausea, vomiting, diarrhoea, abdominal cramps, flushing, dizziness, and bradycardia. Given the depot formulation and slow-release characteristics of the drug, symptoms from overdose may be prolonged. If overdose is suspected, contact your local poison control centre or seek emergency medical attention immediately.
What Are the Side Effects of Lanreotid Amdipharm?
Quick Answer: The most common side effects of lanreotide include gastrointestinal disturbances (diarrhoea, abdominal pain, nausea, flatulence), gallstones, and injection site reactions. Most side effects are mild to moderate and tend to diminish over time with continued treatment.
Like all medicines, Lanreotid Amdipharm can cause side effects, although not everybody gets them. The side effect profile of lanreotide has been well-characterised through extensive clinical trials involving thousands of patients across multiple indications. Understanding the frequency and nature of potential adverse effects helps patients and clinicians to weigh the benefits of treatment against its risks and to manage side effects proactively when they occur.
The frequency categories used below follow the standard classification established by the Council for International Organizations of Medical Sciences (CIOMS) and adopted by the European Medicines Agency (EMA). Side effects are reported based on pooled data from clinical trials and post-marketing surveillance.
Very Common
Affects more than 1 in 10 patients (>10%)
- Diarrhoea — occurs in approximately 26–37% of patients; usually mild to moderate and often improves with continued use
- Abdominal pain — reported in 14–19% of patients; typically localised to the upper abdomen
- Gallstones (cholelithiasis) — develops in 15–30% of patients with long-term use; regular ultrasound monitoring recommended
Common
Affects 1 to 10 in 100 patients (1–10%)
- Nausea and vomiting — particularly during the initial weeks of treatment
- Flatulence — may be accompanied by bloating and abdominal discomfort
- Injection site reactions — pain, nodule formation, induration at the injection site
- Loose stools and steatorrhoea — fatty stools due to reduced pancreatic enzyme secretion
- Dizziness
- Headache
- Fatigue and asthenia
- Hyperglycaemia — elevated blood glucose levels
- Hypoglycaemia — low blood glucose, less common than hyperglycaemia
- Weight changes — either loss or gain
Uncommon
Affects 1 to 10 in 1,000 patients (0.1–1%)
- Bradycardia — slow heart rate; clinically relevant in patients with pre-existing cardiac conditions
- Cholecystitis — inflammation of the gallbladder; may require surgical intervention
- Biliary dilatation — enlargement of bile ducts
- Decreased appetite
- Pruritus (itching) — generalised or localised
- Alopecia (hair loss) — usually mild and reversible
- Raised liver enzymes — typically transient elevations in ALT and AST
Rare
Affects less than 1 in 1,000 patients (<0.1%)
- Pancreatitis — inflammation of the pancreas; characterised by severe abdominal pain radiating to the back
- Allergic reactions — including anaphylaxis (very rare); urticaria, angioedema
- Hypothyroidism — decreased thyroid function requiring thyroid hormone replacement
- QT prolongation — alteration in heart rhythm detected on ECG
Contact your healthcare provider if you experience any side effects that are persistent, severe, or concerning. Seek immediate medical attention if you develop signs of a serious allergic reaction (difficulty breathing, swelling of the face or throat, severe rash), severe abdominal pain that may indicate gallbladder disease or pancreatitis, or signs of significant heart rate changes such as fainting or severe dizziness.
You can also report side effects directly to your national pharmacovigilance authority. In the EU, suspected adverse reactions can be reported via the national reporting systems of each member state. In the UK, the Yellow Card Scheme is available. Reporting helps to provide more information on the safety of this medicine.
How Should You Store Lanreotid Amdipharm?
Quick Answer: Store Lanreotid Amdipharm in a refrigerator at 2–8°C in its original packaging. Do not freeze. The product may be kept at room temperature (up to 25°C) for a single period of up to 24 hours before use.
Proper storage of Lanreotid Amdipharm is essential to ensure the medication retains its efficacy and safety throughout its shelf life. As a peptide-based biological product, lanreotide is sensitive to temperature extremes and light exposure, which can lead to degradation of the active substance and loss of therapeutic activity.
Refrigeration: The pre-filled syringes should be stored in a refrigerator at 2–8°C (36–46°F). Store the syringe in the original sealed pouch and outer carton to protect it from light. Do not remove the syringe from its packaging until immediately before use.
Room temperature: If necessary, Lanreotid Amdipharm may be removed from the refrigerator and kept at room temperature (up to 25°C / 77°F) for a single period of up to 24 hours before administration. This allows the product to reach a more comfortable temperature for injection. However, once removed from refrigeration, the product should not be returned to the refrigerator and must be used within 24 hours or discarded.
Do not freeze: Freezing the product will damage the formulation and render it unusable. If the syringe has been accidentally frozen, it must be discarded.
Shelf life: Check the expiry date printed on the outer carton and blister pack. Do not use the product after the stated expiry date. Do not use the syringe if the solution appears discoloured, contains visible particles, or if the sealed pouch has been damaged.
Disposal: Do not dispose of unused medicines via household waste or wastewater. Return unused or expired syringes to your pharmacist for safe disposal in accordance with local regulations. This helps to protect the environment.
What Does Lanreotid Amdipharm Contain?
Quick Answer: Each pre-filled syringe contains 60 mg of lanreotide (as acetate) as the active ingredient. The solution also contains water for injections and acetic acid for pH adjustment.
Understanding the composition of your medication is important, particularly for patients with known allergies or sensitivities to specific pharmaceutical ingredients. The formulation of Lanreotid Amdipharm has been designed to provide a stable, ready-to-use solution that forms a sustained-release depot upon subcutaneous injection.
Active substance: Each pre-filled syringe contains lanreotide 60 mg (equivalent to approximately 78.6 mg of lanreotide acetate). Lanreotide is an octapeptide analogue of somatostatin with the chemical formula C54H69N11O10S2. Its molecular weight is 1096.34 Da.
Excipients:
- Water for injections — serves as the solvent
- Acetic acid, glacial — used for pH adjustment to ensure stability and optimal depot formation
The product does not contain preservatives, latex, or any animal-derived components. The pre-filled syringe is made of glass with a stainless steel needle and a plunger stopper made of bromobutyl rubber. The syringe is provided in a sealed aluminium laminate pouch to protect the product from moisture and light.
Appearance: Lanreotid Amdipharm is a white to slightly yellow, semi-solid preparation that becomes a viscous solution at the injection temperature. The formation of a gel-like consistency is a normal characteristic of the product and is essential for creating the sustained-release depot at the injection site.
Frequently Asked Questions About Lanreotid Amdipharm
Lanreotide Amdipharm is used to treat acromegaly (a condition caused by excess growth hormone production, usually due to a benign pituitary tumour), gastroenteropancreatic neuroendocrine tumours (GEP-NETs) — which are tumours of the digestive system and pancreas — and to control symptoms of carcinoid syndrome such as severe diarrhoea and flushing. It works by mimicking the natural hormone somatostatin to suppress excess hormone secretion and may also have antiproliferative effects on tumour cells.
Lanreotide Amdipharm is given as a deep subcutaneous injection, typically in the upper outer quadrant of the buttock. The injection is usually administered by a healthcare professional every 28 days. The syringe comes pre-filled with 60 mg of lanreotide. After appropriate training, self-injection or injection by a trained carer may be possible. The injection site should be alternated between left and right buttocks at each visit.
The most common side effects are gastrointestinal in nature, including diarrhoea (affecting approximately 26–37% of patients), abdominal pain, nausea, and flatulence. Gallstones (cholelithiasis) are also very common, developing in 15–30% of patients during long-term treatment. Injection site reactions such as pain, nodule formation, and induration are common. Most side effects are mild to moderate and tend to diminish with continued therapy.
Yes, lanreotide can affect glucose metabolism because it inhibits the secretion of both insulin and glucagon from the pancreas. This may result in hyperglycaemia (high blood sugar) in some patients or, less commonly, hypoglycaemia (low blood sugar). Patients with diabetes or impaired glucose tolerance should monitor their blood sugar more frequently during treatment. Your doctor may need to adjust the doses of any antidiabetic medications you are taking.
Lanreotide Amdipharm pre-filled syringes should be stored in a refrigerator at 2–8°C (36–46°F) in the original packaging to protect from light. The product may be removed from the refrigerator and kept at room temperature (up to 25°C / 77°F) for a single period of up to 24 hours before use, to allow it to reach a more comfortable temperature for injection. Do not freeze. Once removed from refrigeration, do not return to the refrigerator.
Lanreotide Amdipharm is not recommended during pregnancy unless the potential benefit clearly outweighs the potential risk to the foetus. Animal studies have shown some adverse reproductive effects, although no teratogenic effects were observed at therapeutic doses. Women of childbearing potential should use effective contraception during treatment. Breastfeeding is also not recommended during lanreotide therapy due to insufficient data on whether the drug passes into breast milk.
References
- European Medicines Agency (EMA). Summary of Product Characteristics: Lanreotide. Available at: www.ema.europa.eu. Accessed January 2026.
- Caplin ME, Pavel M, Cwikla JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors (CLARINET study). New England Journal of Medicine. 2014;371(3):224-233. doi:10.1056/NEJMoa1316158
- Melmed S, Bronstein MD, Chanson P, et al. A Consensus Statement on acromegaly therapeutic outcomes. Nature Reviews Endocrinology. 2018;14(9):552-561.
- World Health Organization (WHO). WHO Model List of Essential Medicines. 23rd edition. Geneva: WHO; 2023.
- Pavel M, Gross DJ, Benavent M, et al. Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELESTAR trial. The Lancet. 2017;390(10093):627-636.
- British National Formulary (BNF). Lanreotide. National Institute for Health and Care Excellence (NICE). Available at: bnf.nice.org.uk. Accessed January 2026.
- Caron PJ, Bevan JS, Petersenn S, et al. Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. Journal of Clinical Endocrinology & Metabolism. 2014;99(4):1282-1290.
- Oberg K, Knigge U, Kwekkeboom D, Perren A; ESMO Guidelines Working Group. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines. Annals of Oncology. 2012;23(Suppl 7):vii124-vii130.
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors. Version 1.2025.
- Giustina A, Chanson P, Kleinberg D, et al. Expert consensus document: A consensus on the medical treatment of acromegaly. Nature Reviews Endocrinology. 2014;10(4):243-248.
About the Medical Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians in endocrinology, oncology, and clinical pharmacology. Our editorial process follows the GRADE evidence framework and adheres to international medical guidelines from the WHO, EMA, and NICE.
Medical Writing
Content created by specialist physicians with expertise in endocrinology and neuroendocrine tumour management, based on current EMA SmPC data and peer-reviewed clinical evidence.
Medical Review
Independently reviewed by the iMedic Medical Review Board for clinical accuracy, completeness, and adherence to international treatment guidelines.
Evidence Standards
Evidence Level 1A — based on systematic reviews, meta-analyses, and randomised controlled trials following the GRADE framework.
Independence
No pharmaceutical company sponsorship. No commercial funding. Completely independent medical editorial content.